Search

Your search keyword '"Terhaard CH"' showing total 105 results

Search Constraints

Start Over You searched for: Author "Terhaard CH" Remove constraint Author: "Terhaard CH" Database MEDLINE Remove constraint Database: MEDLINE
105 results on '"Terhaard CH"'

Search Results

1. Long-term nephrotoxicity in irradiated pediatric kidney tumor survivors: A systematic review.

2. Clinical value of (dedicated) 3 Tesla and 7 Tesla MRI for cT1 glottic carcinoma: A feasibility study.

3. Systematic review of the diagnostic value of magnetic resonance imaging for early glottic carcinoma.

4. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.

5. Detection of cartilage invasion in laryngeal carcinoma with dynamic contrast-enhanced CT.

6. Indicators for Enteral Nutrition Use and Prophylactic Percutaneous Endoscopic Gastrostomy Placement in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy.

7. Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI.

8. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.

9. Validated guidelines for tumor delineation on magnetic resonance imaging for laryngeal and hypopharyngeal cancer.

10. Influence of FDG-PET on primary nodal target volume definition for head and neck carcinomas.

11. Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.

12. Correlation of human papillomavirus status with apparent diffusion coefficient of diffusion-weighted MRI in head and neck squamous cell carcinomas.

13. Interobserver variation among pathologists for delineation of tumor on H&E-sections of laryngeal and hypopharyngeal carcinoma. How good is the gold standard?

14. Treatment of T3 laryngeal cancer in the Netherlands: a national survey.

15. Diffusion-weighted imaging in head and neck squamous cell carcinomas: a systematic review.

16. Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.

17. GTV delineation in supraglottic laryngeal carcinoma: interobserver agreement of CT versus CT-MR delineation.

18. The accuracy of target delineation in laryngeal and hypopharyngeal cancer.

19. Consequences of tumor planning target volume reduction in treatment of T2-T4 laryngeal cancer.

20. Diffusion-weighted MR imaging in laryngeal and hypopharyngeal carcinoma: association between apparent diffusion coefficient and histologic findings.

21. The importance of actual tumor growth rate on disease free survival and overall survival in laryngeal squamous cell carcinoma.

22. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.

23. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.

24. Importance of tumor volume in supraglottic and glottic laryngeal carcinoma.

25. Diffusion weighted MRI in head-and-neck cancer: geometrical accuracy.

26. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.

27. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial.

28. Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients.

29. Origin of tumor recurrence after intensity modulated radiation therapy for oropharyngeal squamous cell carcinoma.

30. Xerostomia: a day and night difference.

31. Evidence for treatment strategies in sinonasal adenocarcinoma.

32. MUC5B levels in submandibular gland saliva of patients treated with radiotherapy for head-and-neck cancer: a pilot study.

33. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.

34. Validation of imaging with pathology in laryngeal cancer: accuracy of the registration methodology.

35. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.

36. MRI to quantify early radiation-induced changes in the salivary glands.

37. Survival analysis of head and neck squamous cell carcinoma: influence of smoking and drinking.

38. Magnetic resonance imaging at 3.0T for submandibular gland sparing radiotherapy.

39. Parotid gland function after radiotherapy: the combined michigan and utrecht experience.

40. Cytology and histology have limited added value in prognostic models for salivary gland carcinomas.

41. New insights in the vascular supply of the human parotid gland - consequences for parotid gland-sparing irradiation.

42. Improved immobilization using an individual head support in head and neck cancer patients.

43. Parotid gland function after radiotherapy.

44. A comparison of dose-response models for the parotid gland in a large group of head-and-neck cancer patients.

45. Magnetic resonance imaging protocol optimization for delineation of gross tumor volume in hypopharyngeal and laryngeal tumors.

46. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.

47. The prognostic role of comorbidity in salivary gland carcinoma.

48. Sparing the contralateral submandibular gland in oropharyngeal cancer patients: a planning study.

49. [Saliva and intensity modulated radiotherapy].

50. 3D MR sialography as a tool to investigate radiation-induced xerostomia: feasibility study.

Catalog

Books, media, physical & digital resources